VXRT News and Press, Vaxart Inc. From 12/01/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Despite omicron variant chatter propping up even relatively obscure biotech companies , Vaxart (NASDAQ: VXRT ) can’t seem to get in on the conversation. VXRT stock is down 9% today as it appears to be leveling...

Vaxart (NASDAQ:VXRT) has announced the acquisition of its second GMP manufacturing facility. The clinical-stage biotechnology company entered into an agreement with Kindred Bioscience for the purchase of KindredBio's manufacturing equipment and sublease of its GMP manufacturing plant in Burli...

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) has entered into an agreement with Kindred Bioscience, Inc. (“KindredBio”) for the purchase of KindredBio’s manufacturing equipment and sublease of its GMP (Good Manufacturin...

iSpecimen (NASDAQ:ISPC) +70% COVID-19 vaccine stocks surge on worries over new variant Allied Healthcare Products (NASDAQ:AHPI) +68%. Alpha Pro Tech (NYSE:APT) +24% Zoom Video and Peloton take off as new COVID variant revives stay-at-home trade Valneva SE (NASDAQ:VALN) +18...

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2021 in San Diego on Tuesday, November 30, 2021 at 2:4...

A new study published in Cell Host and Microbe has indicated that the VXA-A1.1, an experimental oral tablet flu vaccine developed by Vaxart (NASDAQ:VXRT), offered cellular correlates of protection against the infection caused by the influenza virus. In a Phase 2 human challenge...

STANFORD, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under development by Vaxart, Inc. (NASDAQ: VXRT), had cellular correlates of protection against influenz...

Full data is now available on a preclinical study that Vaxart (VXRT -0.8%) conducted in hamsters demonstrating the potential efficacy of its oral COVID-19 vaccine. Results have been published in The Journal of Infectious Diseases. In the study, hamsters were vaccinated orally or intranasally ...

In an environment where injection-type vaccines are proving to offer somewhat reduced protection against the delta variant, the risks of being infected and transmitting the virus to others remain high. In this case, Vaxart's oral tablet vaccine, not to be confused with the antiviral p...

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) announced today the Journal of Infectious Diseases has published complete data from Vaxart’s preclinical Hamster Challenge Study. The study shows Vaxart’s COVID-19 oral vaccine candidate...